LONG BEACH, Calif. — Iluvien for diabetic macular edema demonstrated longer-lasting intervals between injections and noninferior visual acuity gains vs. aflibercept but did not meet the primary endpoint of the NEW DAY study.“Although the NEW DAY study …
Author: Healio ophthalmology
Treatment of thyroid eye disease requires team effort
Ophthalmologists are a critical part of the medical team needed to treat thyroid eye disease.An endocrinologist is usually the team leader, but ophthalmologists, diagnostic and therapeutic radiologists, along with an otolaryngologist/audiologist are ot…
Study: Same-day exam safe after vitreoretinal surgery
LONG BEACH, Calif. — A day 0 exam may help ease logistical issues after vitreoretinal surgery, according to a study presented at the American Society of Retina Specialists annual meeting.Christina Y. Weng, MD, MBA, FASRS, said a day 1 postoperative exa…
FDA approves once-daily Vizz for presbyopia
The FDA approved Vizz for the treatment of presbyopia in adults, according to a press release from Lenz Therapeutics.Once-daily Vizz (aceclidine ophthalmic solution 1.44%) contracts the iris sphincter muscle, creating a pinhole effect to extend depth o…
Surgeon volume not linked with retinal detachment revision
LONG BEACH, Calif. — Surgical volume was not associated with retinal detachment revision, according to a study presented at the American Society of Retina Specialists annual meeting.“The incidence of retinal detachment is about one in 10,000, and we’ve…
Previous retinal tear, detachment may increase recurrence risk
LONG BEACH, Calif. —A previous retinal tear or retinal detachment may be a risk factor for developing a recurrent phakic retinal tear after cataract surgery, according to a speaker.“We obviously know that retinal tears are a significant concern because…
Andrew G. Lee shares neuro-ophthalmology advice for retina specialists
LONG BEACH, Calif. — In this Healio Video Perspective from the American Society of Retina Specialists annual meeting, Andrew G. Lee, MD, discusses when retina experts should refer patients to a neuro-ophthalmologist.According to Lee, every retina speci…
Alcon launches Tryptyr for dry eye in US
Alcon launched Tryptyr, a treatment for the signs and symptoms of dry eye disease, in the U.S.Tryptyr (acoltremon ophthalmic solution 0.003%) is a TRPM8 receptor agonist that showed a “statistically significant increase in natural tear production as ea…
Sunir Garg shares solutions to complex surgical cases
LONG BEACH, Calif. — In this Healio Video Perspective from the American Society of Retina Specialists annual meeting, Sunir J. Garg, MD, FACS, FASRS, presented lessons learned from two complex surgical cases.In the first case, a patient with uveitis wh…
What can I do to stay as healthy as possible in retirement?
A 65-year-old recently retired man presents to the office for his “Welcome to Medicare” exam.The patient retired from his job as an accountant about 3 months ago. His only past medical history, consists of hyperlipidemia and impaired fasting glucose. H…
Re-Vana, Boehringer Ingelheim announce strategic collaboration
LONG BEACH, Calif. — Re-Vana Therapeutics is collaborating with Boehringer Ingelheim to develop extended-release therapies for ophthalmic diseases, according to a press release.At the American Society of Retina Specialists annual meeting, Re-Vana CEO M…
Healio earns seven APEX awards for publication excellence
Healio took home seven APEX awards this year, including two exclusive Grand Awards.“We are immensely proud of our editorial, design and marketing teams. The APEX Awards’ continued recognition of Healio is a testament to the quality of work these teams …
Bascom Palmer named top ophthalmology hospital for 24th time
Bascom Palmer Eye Institute in Miami has been ranked as the nation’s best ophthalmology hospital for the 24th time by U.S. News & World Report.The institute is part of the University of Miami Health System and the University of Miami Miller School of M…
U.S. News announces 2025-2026 best hospitals
U.S. News & World Report announced its 2025-2026 Best Hospitals rankings Tuesday.This year’s list includes 504 regional hospitals “that have demonstrated superior outcomes,” 20 of which were named in the Honor Roll, according to a press release.“For mo…
Strive to find, harness motivation as a practice owner
“Good, better, best. Never let it rest. ‘Til your good is better and better is best.”– St. Jerome“Perseverance is not a long race; it is many short races one after the other.”– Walter ElliotIn business, we talk a lot about motivation. Motivation is a f…
Retina care evolves with latest sustained-release therapeutic agents
The development of drug delivery platforms that offer sustained release of therapeutic agents in the retina represents a vital evolution in ophthalmic practice.While the ongoing emergence of effective drugs and biologics for the treatment of retinal co…
Aflibercept biosimilars benefit patients globally
FORT LAUDERDALE, Fla. — In this Healio Video Perspective from the Retina World Congress, Ashish Sharma, MBBS, MS, gives an update on aflibercept biosimilars around the world.According to Sharma, there are five FDA-approved aflibercept biosimilars, with…
Wills Eye Hospital appoints Julia A. Haller, MD, as CEO
Julia A. Haller, MD, ophthalmologist-in-chief at Wills Eye Hospital, has been named CEO, succeeding Joseph P. Bilson, according to a press release.In her expanded role, Haller will oversee patient care, financial performance and strategic planning. She…
Treatment for thyroid eye disease in an exciting era of growth
There was a lot of excitement when Tepezza became the first drug approved for the treatment of thyroid eye disease in January 2020. Then, COVID hit.“Sort of terrible timing with regards to that,” Richard C. Allen, MD, PhD, FACS, said. “There was a lot …
Eylea HD extends dosing intervals in DME, wet AMD
SALT LAKE CITY — In this Healio Video Perspective from the ARVO meeting, Michael Javaheri, MD, overviews real-world data on Eylea HD in diabetic macular edema and wet age-related macular degeneration.Javaheri reported an average treatment interval of 7…